Mammalian Development and the Generation
of Mouse Models of Human Genetic Disorders
The long range goals of our work are
directed towards an understanding of mammalian development on a
genetic and molecular level and the derivation of mouse models
for human genetic disorders. Current methods of homologous
recombination in embryonic stem cells allow generation of mice
with predetermined mutations. Our strategies include the
production of mice carrying mutations which are expressed only in
specific lineages as well as mice which carry large fragments of
DNA derived from yeast artificial chromosomes (YACs). We are
using these powerful approaches to investigate the function of
specific genes which are important for the following aspects of
mouse development, disease, and cancer.
DNA Methylation: Despite a large
body of evidence, the importance of DNA methylation in vertebrate
gene control has remained a controversial issue because of the
indirect and correlative nature of many studies in the field.
Over the years, DNA methylation has been hypothesized to be
involved in numerous processes including X inactivation, genomic
imprinting, virus latency, carcinogenesis, aging, and the
regulation of tissue-specific gene expression during development.
We have undertaken a direct approach to defining the role of DNA
methylation in development and have generated an allelic series
with partial loss of function and null alleles of the only known
methyltransferase (MTase) gene in mammals. Mutant embryos are
unable to maintain normal levels of genomic methylation and die
at midgestation, a result which establishes the essential role of
DNA methylation in development. We are using this mutant strain
to investigate the role of methylation in genomic imprinting,
X-inactivation and cancer. A potential problem in our approach is
the embryonic lethality caused by the mutation of the MTase gene.
This has prompted us to generate a mutant allele which can be
expressed in a stage and tissue specific manner which will allow
to study the role of DNA methylation in the postnatal animal.
Genomic Imprinting: Imprinted genes
are expressed either from the maternal or the paternal allele but
not from both. Using the MTase mutant mice we have shown that
normal DNA methylation levels are crucial for the maintenance of
the imprint and for monoalleleic expression of the genes, leading
to the hypothesis that gamete-specific MTase activities install
methylation marks on imprinted genes during oogenesis and
spermatogenesis, respectively. Our results suggest that at least
four different DNA MTase activities are expressed in mammals: (i)
a hemi-MTase in all cells; (ii) a de novo MTase in ES
cells and in embryos prior to gastrulation; a specific de novo
MTase in (iii) spermatogenesis and (iv) oogenesis which
recognizes paternally or maternally methylated imprinted genes,
respectively. Only the hemi-MTase has been cloned and a major
challenge will be to identify the other activities. We are,
therefore, using several approaches to define the de novo MTase
which establishes the early embryonic methylation pattern and may
be involved in the genesis of cancer.
X-Inactivation: The mammalian dosage
pathway is activated by a mechanism that counts the number of
chromosomes. The "n-1" rule dictates that in diploid
cells a single X chromosome remains active regardless of the
total number of X chromosomes: XY males have no inactive X,
normal females with two Xs have one inactive X and individuals
with three Xs have two inactive X chromosomes. X chromosome
inactivation in mammals requires expression of the Xist
gene which maps to the X chromosome inactivation center (Xic) and
encodes an untranslated nuclear RNA. We have used homologous
recombination approaches as well as the transfer of large
fragments of DNA into ectopic sites to define the genetic and
epigenetic control of X inactivation. Our results indicate that (i) Xist RNA is necessary for initiation and propagation
of the inactivation process; (ii) DNA methylation is crucial for
shielding the active X chromosome against the inactivation
process; (iii) that a 450 kb fragment of DNA carrying the Xist
gene acts as an inactivation center and is sufficient for
initiation, propagation and maintenance of the inactive state.
Also, the elements for counting and choosing X chromosomes to
execute the "n-1 rule" are part of the transgene.
Cancer: The involvement of DNA
methylation in cancer has been controversial: both
hypomethylation as well as hypermethylation have been associated
with malignant transformation. When the MTase mutation was
introduced into mice with a genetic predisposition to colon
cancer, a surprising result was obtained: the MTase enzyme level
directly correlated with the development of cancer. This
represents a novel concept of the role of DNA methylation in
carcinogenesis and argues that the MTase enzyme itself acts as an
oncogenic determinant. Also, as suggested by work with
prokaryotes, DNA methylation may be crucial for DNA repair and
for maintaining the stability of the genome. Alternatively, DNA
methylation may affect cancer initiation by an epigenetic
mechanism, i.e. the alteration of gene expression. We are
pursuing experiments to distinguish between these alternatives.
Neurotrophins: Neurotrophins (NGF, BDNF, NT-3, NT-4) are important survival factors for the
developing nervous system. It has been postulated that
neurotrophins may be useful for the function of postnatal neurons
and could be used in the treatment of degenerative diseases such
as Alzheimer's or ALS. To directly test the role of NT-3 in
postnatal life, we have generated a "floxed" allele
which allows the deletion of the gene by stage-specific
expression of the Cre recombinase. The Cre recombinase has been
targeted to various parts of the brain including the hippocampus
and we are assessing whether the lack of NT-3 in the adult may
lead to specific neuronal deficits.